Skip to main content
OpenTrials
Completed

NCT Number: NCT03812276

Neodent Implantable Devices of GM Line

Acqua GM (Grand Morse) Helix implants present an optimized implant design with adapted treatment protocol, allowing for treatment of patients with different bone qualities.

The objective of the study is to prospectively collect clinical data to confirm the long-term safety and clinical performance of Acqua GM Helix implants and GM prosthetic abutments in daily dental practice setting, by means of success and survival rates of these devices.

Devices will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (instructions for use). patients will be followed for 36 months after implant placement.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Instituto Latino Americano de Pesquisa e Ensino Odontológico (ILAPEO), Curitiba, Paraná, Brazil

Loading trial locations.

About this study

The study protocol was reviewed and approved by an Ethics Committee (CE) in Brazil.

The sample will be prospectively and consecutively selected and will consist of patients who are 18 years of age or older, who are in need of one or more dental implants and who qualify for placement of Neodent GM Helix implants. Informed consent in writing will be obtained from each patient participating in the study prior to any study related procedure.

Neodent Acqua GM Helix implants will be placed under local anesthesia and with adequate bone bed preparation, as recommended by the manufacturer. Multiple implants may be placed in a single subject. Implants will be placed 2mm below the alveolar ridge.

The selection of the prosthetic component and loading protocol (late or immediate) will be conducted according to the need of each subject and to the manufacturer's instructions (IFU). Thus, implant immediate loading may be performed (at the discretion of the surgeon) when primary stability reach at least 32 N.cm and the patient present physiological occlusion.

Data concerning the studied variables will be collected by fulfilling the Case Report Form (CRF), in the following stages: First visit (Screening); T0 - Implant(s) placement; TL - Implant loading; T6, T12, T24 and T36 - 6, 12, 24 and 36 months, respectively, after implant placement. A visit window of more or less one month is eligible for each of the planned intervals.

Standardized digital periapical radiographs, computed tomography scans and photographs will be obtained in an usual daily practice frequency, as determined by the investigator.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older;
  • Need of one or more dental implants;
  • Qualify for placement of Neodent GM Helix implants.

Exclusion criteria

As exclusion criteria, solely the device contraindications according to the IFU (instructions for use) will be applied:

  • Signs of allergy or hypersensitivity to the chemical ingredients of the material: titanium alloy;
  • Presence of acute inflammatory or infectious processes in live tissue;
  • Unsuitable bone volume or quality;
  • Serious medical problems (e.g. bone metabolism disorders, blood clotting disorders, unsuitable healing capacity);
  • Insufficient oral hygiene;
  • Incomplete jawbone growth;
  • Patient uncooperative and not motivated;
  • Abuse of drugs or alcohol;
  • Psychosis;
  • Prolonged functional disorders which resist any treatment with medications;
  • Xerostomia;
  • Weakened immunological system;
  • Diseases which require the use of steroids;
  • Uncontrolled endocrinological diseases;
  • Pregnancy.

Treatment and study plan

dental implants

Device

Dental Implants will be used according to standard routine in daily practice, according to all indications as specified by the manufacturer in the IFU (informations for use).

Primary outcomes

  1. Implant survival and success rates

    Time frame: 36 months after implant placement

    Implant survival will be defined as no loss of the implant at each follow-up. Evaluation of implant success will be assessed based on the criteria proposed by Buser et al. (1990).

Secondary outcomes

  1. Implant survival and success rates

    Time frame: 6, 12 and 24 months after implant placement

    Implant survival will be defined as no loss of the implant at each follow-up. Evaluation of implant success will be assessed based on the criteria proposed by Buser et al. (1990).

  2. Prosthetic survival and success rates

    Time frame: 12, 24 and 36 months after implant placement

    Prosthetic survival will be assessed as the prosthesis remaining in situ at each follow-up, irrespective of its condition. Success will be defined as the prosthesis that remained unchanged and did not require any intervention during the entire observational period.

  3. Patient Satisfaction: OHIP-14 (Oral Health Impact Profile) questionnaire

    Time frame: 6, 12, 24 and 36 months after implant placement

    The Portuguese translation of OHIP-14 [18,19] questionnaire will be used to assess Oral Health Related Quality of Life (OHRQoL), as a measure of patient satisfaction with treatment. Scores will range from 0 (absence of negative impacts on oral health) to 28 (high frequency of negative impacts on oral health).

  4. Clinician Satisfaction: VAS (Visual Analogue Scale) questionnaire

    Time frame: Implant placement, 12, 24 and 36 months after implant placement

    The assessment will be performed by means of a questionnaire using a visual analog scale (VAS) in the form of a 10 cm horizontal line, where 0 (left end) indicates minimum satisfaction and 10 (right end) indicates maximum satisfaction. The clinician will be instructed to mark the position considered to best represent their degree of general satisfaction with patient treatment. The score will be measured in centimeters from the left end of the line to the marked point.

  5. Rate of adverse events related to the implant, prosthesis, surgery and oral health

    Time frame: Implant placement, 6, 12, 24 and 36 months after implant placement

    Determined by inquiring with the patient and clinical evaluation.

Sponsors and collaborators

Lead sponsor

Neodent

Industry

Registry information

Official study title

Prospective Observational Study of Neodent Implantable Devices of GM Line

Important dates

Study start
2019
Primary completion
2023
Study completion
2023
First posted
Jan 23, 2019
Registry last updated
Feb 10, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.